During SET and after NOGGIN treatment, we detected downregulation of SOX17 and upregulation of SOX2. In fact, SOX17 expression is restricted to CIS and seminomas, while SOX2 is highly expressed in ECs [2]. The gene discussed is SOX17; the disease is in situ carcinoma.